PL2293819T3 - Sposób diagnozowania raków z ekspresją skróconego wariantu receptora Her2 - Google Patents

Sposób diagnozowania raków z ekspresją skróconego wariantu receptora Her2

Info

Publication number
PL2293819T3
PL2293819T3 PL09772265T PL09772265T PL2293819T3 PL 2293819 T3 PL2293819 T3 PL 2293819T3 PL 09772265 T PL09772265 T PL 09772265T PL 09772265 T PL09772265 T PL 09772265T PL 2293819 T3 PL2293819 T3 PL 2293819T3
Authority
PL
Poland
Prior art keywords
her2 receptor
receptor variant
cancers expressing
diagnosing cancers
truncated her2
Prior art date
Application number
PL09772265T
Other languages
English (en)
Inventor
López Joaquín Arribas
Kim Pedersen
Pier-Davide Angellini
Palau Josep Lluis Parra
Sirle Laos
Torres José Baselga
Original Assignee
Fundacio Privada Institut De Recerca Hospital Univ Vall Hebron
Fundacio Privada Inst Catalana De Recerca I Estudis Avancants
Fundacio Privada Inst Dinvestigacio Oncològica De Vall Hebron
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacio Privada Institut De Recerca Hospital Univ Vall Hebron, Fundacio Privada Inst Catalana De Recerca I Estudis Avancants, Fundacio Privada Inst Dinvestigacio Oncològica De Vall Hebron filed Critical Fundacio Privada Institut De Recerca Hospital Univ Vall Hebron
Publication of PL2293819T3 publication Critical patent/PL2293819T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Peptides Or Proteins (AREA)
PL09772265T 2008-06-02 2009-06-05 Sposób diagnozowania raków z ekspresją skróconego wariantu receptora Her2 PL2293819T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES200801652A ES2342646B1 (es) 2008-06-02 2008-06-02 Metodo de diagnostico de canceres que expresan el receptor her-2 o sus variantes truncadas.
PCT/EP2009/056976 WO2010000565A1 (en) 2008-06-02 2009-06-05 Method for diagnosing cancers expressing the her2 receptor or its truncated variants
EP09772265.6A EP2293819B1 (en) 2008-06-02 2009-06-05 Method for diagnosing cancers expressing a truncated her2 receptor variant

Publications (1)

Publication Number Publication Date
PL2293819T3 true PL2293819T3 (pl) 2015-04-30

Family

ID=40911029

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09772265T PL2293819T3 (pl) 2008-06-02 2009-06-05 Sposób diagnozowania raków z ekspresją skróconego wariantu receptora Her2

Country Status (21)

Country Link
US (1) US8389227B2 (pl)
EP (1) EP2293819B1 (pl)
JP (2) JP5753079B2 (pl)
KR (2) KR101785117B1 (pl)
CN (1) CN102202692B (pl)
AU (2) AU2009265921B2 (pl)
BR (1) BRPI0914969A2 (pl)
CA (1) CA2727365A1 (pl)
CY (1) CY1115798T1 (pl)
DK (1) DK2293819T3 (pl)
EA (1) EA025218B1 (pl)
ES (2) ES2342646B1 (pl)
HK (1) HK1157658A1 (pl)
HR (1) HRP20141158T1 (pl)
IL (1) IL209769A (pl)
MX (1) MX2010013419A (pl)
PL (1) PL2293819T3 (pl)
PT (1) PT2293819E (pl)
SI (1) SI2293819T1 (pl)
WO (1) WO2010000565A1 (pl)
ZA (1) ZA201009010B (pl)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002081649A2 (en) * 2001-04-06 2002-10-17 The Trustees Of The University Of Pennsylvania ErbB INTERFACE PEPTIDOMIMETICS AND METHODS OF USE THEREOF
WO2009086197A1 (en) 2007-12-20 2009-07-09 Monogram Biosciences, Inc. Her-2 diagnostic methods
ES2342646B1 (es) * 2008-06-02 2011-04-26 Institut De Recerca Hospital Universitari Vall Hebron Metodo de diagnostico de canceres que expresan el receptor her-2 o sus variantes truncadas.
WO2010065568A2 (en) 2008-12-01 2010-06-10 Laboratory Corporation Of America Holdings METHODS AND ASSAYS FOR MEASURING p95 AND/OR p95 IN A SAMPLE AND ANTIBODIES SPECIFIC FOR p95
ES2535723T3 (es) 2009-01-15 2015-05-14 Laboratory Corporation Of America Holdings Métodos de determinación de la respuesta del paciente mediante la medición de Her-3
AU2010248884B2 (en) * 2009-05-14 2015-04-02 Nestec S.A. Biomarkers for determining sensitivity of breast cancer cells to HER2-targeted therapy
PT2330131E (pt) * 2009-12-07 2015-01-14 Fundació Privada Institució Catalana De Recerca I Estudis Avancats Anticorpos contra a variante truncada de her-2 ctf-611
CN103102414B (zh) * 2013-02-04 2014-08-27 无锡傲锐东源生物科技有限公司 抗her2蛋白单克隆抗体及其用途
SG11201508878WA (en) 2013-05-01 2015-11-27 Five Prime Therapeutics Inc Methods of treating cancer
WO2017019623A2 (en) 2015-07-26 2017-02-02 Molecular Templates, Inc. Cell-targeting molecules comprising shiga toxin a subunit effectors and cd8+ t-cell epitopes
ES2864124T3 (es) 2014-03-11 2021-10-13 Molecular Templates Inc Proteínas que comprenden regiones de unión, regiones efectoras de la subunidad A de toxina Shiga y motivos señal de localización de retículo endoplasmático carboxi terminal
SI3604333T1 (sl) 2014-03-11 2021-08-31 Molecular Templates, Inc. Proteini, ki obsegajo aminoterminalne proksimalne Shiga toksin podenota A efektorske regije in celico-ciljajoče vezavne regije imunogobulinskega tipa, ki so sposobne specifične vezave CD38
PT3303373T (pt) 2015-05-30 2020-07-14 Molecular Templates Inc Estruturas de subunidade a de toxina shiga desimunizadas e moléculas de direcionamento celular compreendendo as mesmas
EP3455260B1 (en) 2016-05-12 2022-07-06 Agency for Science, Technology and Research Anti-erbb-2 antibodies and uses thereof
ES2897217T3 (es) 2016-09-30 2022-02-28 Hoffmann La Roche Anticuerpos biespecíficos frente a p95HER2
AU2018213194B2 (en) 2017-01-25 2023-01-12 Molecular Templates, Inc. Cell-targeting molecules comprising de-immunized, Shiga toxin A Subunit effectors and CD8+ T-cell epitopes
KR20200143634A (ko) 2018-04-17 2020-12-24 몰레큘러 템플레이츠, 인코퍼레이션. 탈면역된 시가 독소 a 서브유닛 스캐폴드를 포함하는 her2-표적화 분자
CN110172448B (zh) * 2019-05-30 2020-07-28 中南大学湘雅二医院 一种滑膜肉瘤细胞系hSS-005R及其子代细胞系
KR20220042161A (ko) 2019-07-23 2022-04-04 엥스띠뛰 퀴리 Suv39h1에 결함이 있는 면역 세포
CN110865184B (zh) * 2019-12-04 2023-04-07 广州医科大学附属第三医院（广州重症孕产妇救治中心、广州柔济医院） Srsp蛋白和srsp抗原表位肽的应用及诊断和治疗肿瘤的产品
EP3915576A1 (en) 2020-05-28 2021-12-01 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Chimeric antigen receptors specific for p95her2 and uses thereof
WO2023126458A1 (en) 2021-12-28 2023-07-06 Mnemo Therapeutics Immune cells with inactivated suv39h1 and modified tcr
EP4253418A1 (en) 2022-03-29 2023-10-04 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Immune cells expressing chimeric antigen receptors and bispecific antibodies and uses thereof
EP4279085A1 (en) 2022-05-20 2023-11-22 Mnemo Therapeutics Compositions and methods for treating a refractory or relapsed cancer or a chronic infectious disease
WO2024062138A1 (en) 2022-09-23 2024-03-28 Mnemo Therapeutics Immune cells comprising a modified suv39h1 gene

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
WO1996006863A1 (en) 1994-08-30 1996-03-07 University Of Dundee Agents for inducing apoptosis and applications of said agents in therapy
WO1998006863A1 (en) * 1996-08-14 1998-02-19 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services A vector for polynucleotide vaccines
US7371376B1 (en) * 1996-10-18 2008-05-13 Genentech, Inc. Anti-ErbB2 antibodies
ZA9811162B (en) * 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
CA2374085C (en) 1999-05-14 2015-12-29 Genentech, Inc. Tumour treatment with anti-erbb2 antibodies
US6627196B1 (en) * 1999-08-27 2003-09-30 Genentech, Inc. Dosages for treatment with anti-ErbB2 antibodies
US20060204966A1 (en) * 2003-08-01 2006-09-14 Spector Neil L Treatment of cancers expressing p95 erbb2
JP2006316040A (ja) * 2005-05-13 2006-11-24 Genentech Inc Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
ES2342646B1 (es) * 2008-06-02 2011-04-26 Institut De Recerca Hospital Universitari Vall Hebron Metodo de diagnostico de canceres que expresan el receptor her-2 o sus variantes truncadas.
WO2010065568A2 (en) * 2008-12-01 2010-06-10 Laboratory Corporation Of America Holdings METHODS AND ASSAYS FOR MEASURING p95 AND/OR p95 IN A SAMPLE AND ANTIBODIES SPECIFIC FOR p95

Also Published As

Publication number Publication date
CA2727365A1 (en) 2010-01-07
EA201001874A1 (ru) 2011-08-30
AU2009265921A1 (en) 2010-01-07
KR101785117B1 (ko) 2017-11-07
ES2342646B1 (es) 2011-04-26
KR20160140974A (ko) 2016-12-07
KR20110031187A (ko) 2011-03-24
AU2015202854A1 (en) 2015-06-18
US8389227B2 (en) 2013-03-05
IL209769A (en) 2016-04-21
CY1115798T1 (el) 2017-01-25
CN102202692A (zh) 2011-09-28
CN102202692B (zh) 2014-03-12
EP2293819A1 (en) 2011-03-16
JP5753079B2 (ja) 2015-07-22
ES2528132T3 (es) 2015-02-04
JP2011525175A (ja) 2011-09-15
HK1157658A1 (en) 2012-07-06
DK2293819T3 (en) 2014-12-08
HRP20141158T1 (hr) 2015-02-13
US20090311262A1 (en) 2009-12-17
AU2009265921B2 (en) 2015-04-02
WO2010000565A1 (en) 2010-01-07
EP2293819B1 (en) 2014-09-03
SI2293819T1 (sl) 2015-01-30
EA025218B1 (ru) 2016-12-30
PT2293819E (pt) 2014-12-09
ES2342646A1 (es) 2010-07-09
ZA201009010B (en) 2012-03-28
IL209769A0 (en) 2011-02-28
JP2015214546A (ja) 2015-12-03
MX2010013419A (es) 2011-08-15
BRPI0914969A2 (pt) 2015-10-20

Similar Documents

Publication Publication Date Title
PT2293819E (pt) Método para diagnosticar cancros que expressam o recetor her2 ou as suas variantes truncadas
HK1163935A1 (en) Method for making via interconnection
HK1164811A1 (en) Atv having arrangement for a passenger
EP2244908A4 (en) HEADREST FOR CARS
IL208392A (en) Estrogen receptor ligands
EP2341449A4 (en) METHOD FOR OBTAINING INFORMATION ASSOCIATED WITH A LOCATION
HK1133283A1 (zh) 種癌症篩檢的方法
EP2401162A4 (en) METHOD OF USE OF VOID PANTOGRAPHS
SI2330131T1 (sl) Protitelesa proti HER2 skrajšani varianti CTF-611
IL215669A0 (en) A method for screening cancer
IL211424A0 (en) Method for diagnostic marker development
HK1133231A1 (en) Method for producing a multi-layered object
EP2296469A4 (en) KAPPA OPIOID RECEPTOR LIGANDS
GB0806656D0 (en) Novel estrogen receptor ligands
EP2364963A4 (en) PROCESS AND PREPARATION OF OLEFIN
GB0817221D0 (en) Novel estrogen receptor ligands
HK1151764A1 (en) Recess filling apparatus
GB0806657D0 (en) Novel estrogen receptor ligands
GB0811563D0 (en) Apparatus for emptying a cistern
GB0806074D0 (en) Novel estrogen receptor ligands
HK1129991A2 (en) A forming method for three-colour-scissors
TWI346613B (en) A method for forming a structure
GB0919939D0 (en) Apparatus for extending accomodation within a vehicle
EP2377657A4 (en) METHOD FOR OBTAINING A PART MADE FROM A FIRE-RESISTANT MATERIAL
GB0803092D0 (en) Method for predicting a future property